RxDoctor Payments Data

Sean Green, PA

Physician Assistant · Canyon, TXNPI 1679585517

Payments from drug & device makers

$1,356in general payments, 2019–2025

Across 83 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$243
  • AstraZeneca$214
  • AbbVie$175
  • Pfizer$105
  • Biohaven Pharmaceutical Holding Company Ltd.$102
  • Novo Nordisk$97
  • plus $421 from 16 others

What the payments were for

  • Food & beverage$1,356100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,356 in reported general payments places this provider in the 70th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$140,703
Medicare patients
407
Services billed
5,555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$48,852
MounjaroTirzepatide25$32,263
FarxigaDapagliflozin Propanediol17$27,503
EliquisApixaban24$23,469
JardianceEmpagliflozin14$19,357
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,523
Combivent RespimatIpratropium/Albuterol Sulfate12$5,702
PaxlovidNirmatrelvir/Ritonavir27$4,226
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,615
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,529
SymbicortBudesonide/Formoterol Fumarate11$2,629
Levothyroxine Sodium208$2,257
LantusInsulin Glargine,hum.Rec.Anlog14$1,438
Albuterol Sulfate HfaAlbuterol Sulfate45$1,373
Pantoprazole Sodium96$1,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$97$48,85243 claims
Lilly USA, LLCMounjaro$50$32,26325 claims
AstraZenecaFarxiga, Symbicort$214$30,13228 claims
PfizerEliquis, Paxlovid$105$27,69451 claims
GSKTrelegy Ellipta$243$16,52316 claims
AbbVieSynthroid$175$46512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Canyon

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →